LivaNova delivered a robust third quarter in 2025, achieving double-digit revenue growth across both reported and organic bases, driven by strong performance in its Cardiopulmonary and Neuromodulation segments. The company also demonstrated significant operating margin expansion and cash generation, leading to an upward revision of its full-year 2025 revenue, adjusted EPS, and adjusted free cash flow guidance.

LivaNova delivered a robust second quarter in 2025, achieving $352.5 million in revenue, a 10.7% increase year-over-year. The company reported GAAP diluted EPS of $0.50 and adjusted diluted EPS of $1.05, demonstrating strong financial performance driven by growth in both Cardiopulmonary and Neuromodulation segments. LivaNova also raised its full-year 2025 guidance for revenue, adjusted EPS, and adjusted free cash flow.

LivaNova PLC announced robust first-quarter 2025 results, with revenue increasing by 7.4% on a reported basis and 10.4% organically. The company reported a GAAP diluted loss per share of $6.01 due to a significant environmental liability, but adjusted diluted earnings per share reached $0.88. Strong performance in Cardiopulmonary and Neuromodulation segments, along with key regulatory milestones for the aura6000™ System, contributed to the positive quarter.

LivaNova PLC reported a 3.8% increase in fourth-quarter revenue, reaching $321.8 million. U.S. GAAP diluted earnings per share was $1.02, while adjusted diluted earnings per share was $0.81. The company issued full-year 2025 guidance, expecting revenue to grow between 5.0% and 6.0% on a constant-currency basis and adjusted diluted earnings per share to be in the range of $3.65 to $3.75.

LivaNova reported a strong Q4 2023, with revenue increasing by 12.8% to $310.1 million and U.S. GAAP diluted earnings per share of $0.30. Adjusted diluted earnings per share was $0.87. The company provided full-year 2024 guidance, expecting revenue growth between 4% and 5% on a constant-currency basis and adjusted diluted earnings per share in the range of $2.95 to $3.05.

LivaNova PLC reported a 1.8% increase in fourth-quarter revenue, reaching $274.9 million, and a U.S. GAAP diluted earnings per share of $0.03. The company experienced growth across all regions, particularly in the Cardiopulmonary and Neuromodulation business units. Adjusted diluted earnings per share were $0.81.

LivaNova PLC reported a slight increase in worldwide sales from continuing operations for Q4 2021, with significant growth when excluding the divested Heart Valves business. The company's execution met or exceeded the high end of full-year guidance, driven by Neuromodulation and Cardiopulmonary sales. Adjusted diluted earnings per share was $0.57.

LivaNova's Q4 2020 sales were $269.6 million, a decrease of 6.3% compared to the previous year. The company reported a GAAP diluted loss per share of $5.74, while adjusted diluted earnings per share were $0.71. The results were affected by the COVID-19 pandemic, but sales showed sequential improvement compared to Q3 2020.

LivaNova reported a decrease in worldwide sales by 10.6% and a diluted loss per share of $0.30 for Q3 2020. However, the company saw sequential improvement in all business segments, led by U.S. Epilepsy and Advanced Circulatory Support (ACS).

LivaNova reported a significant decrease in sales for Q2 2020 due to the impact of COVID-19 on procedure volumes and capital equipment purchases. The company responded by reducing expenses and improving liquidity. While COVID-19 continues to impact the business, there are encouraging signs of gradual improvement in procedure volumes and new product releases.

LivaNova's first quarter results were impacted by COVID-19, with a decrease in worldwide sales of 3.4% on a reported basis. GAAP diluted earnings per share were $0.79, and adjusted diluted earnings per share were $0.33. The company is closely monitoring the COVID-19 situation and taking actions to strengthen its liquidity position.

LivaNova PLC reported a decrease in worldwide sales by 3.2 percent and a GAAP diluted loss per share of $2.96 for Q4 2019. The adjusted diluted earnings per share were $1.00. The company faced challenges due to a component supplier issue for oxygenators and execution problems in the Rest of World region.